By Melissa Bailey
Originally published on November 30, 2015
Here is an excerpt:
“Nobody wants conflict-of-interest rules to stop basic research if the conflict can be managed,” he said.
The school also lifted the $30,000 cap for publicly traded companies, saying instead that faculty who accept sponsored research from a company cannot own equity amounting to over 1 percent of that company’s value.
Dr. Donald Ingber, who directs Harvard’s Wyss Institute for Biologically Inspired Engineering, called the changes “subtle” but “a move in the right direction.”
“Whenever there’s greater flexibility, it increases the likelihood of greater translation” of discoveries into clinical applications, he said, which is the goal of the Wyss.
“The higher the wall, the more difficult it is to jump over that wall,” he said. “This’ll make it a little bit easier to collaborate.”
The entire article is here.